Moreover, molecular analyses have shown that the CDK4/6-Rb axis is dysregulated in approximately 80% of GBM cases [9]; therefore, the inhibition of CDKs may be a promising treatment strategy against GBM. This evidence concerns the gene RB1 and glioblastoma.